Breaking News

NGen Invests $10.5M to Support Commercial Scale Manufacturing of Cell & Gene Therapies in Canada

The project consortium, led by OmniaBio, will develop advanced platform technologies focused on automated and closed-system manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

Next Generation Manufacturing Canada (NGen), the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing, has announced a $10.5 million contribution to a $34.8 million project led by OmniaBio Inc. and partners ExCellThera, MorphoCell Technologies, Aspect Biosystems, and CATTI.   Biomanufacturing, which involves complex infrastructure and expertise to manufacture and supply new advanced therapies, does not currently exist on a commercial scale in Canada fo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters